Tech Transfers 3X Faster: How QbDVision Made it Possible

In an age of digital transformation, the life sciences still struggle with an age-old challenge.

For businesses capable of scientific marvels, pharma and biotech companies have a bewilderingly hard time moving information and processes from one place to another. 

Tech transfers – an inevitable and recurring step in every drug development pathway – continue to bedevil the industry, bloat timelines, strain budgets, and delay the launch of promising new therapies. Today it takes 24-30 months on average to transition a product and its processes from one site to another, and personnel costs alone have ballooned to $38-389MM per transfer.

So how has this essential step been left behind by all the innovation that has come to the industry’s discovery, clinical development, and commercial functions? 

There are many theories on why tech transfers are particularly resistant to transformation. But as a major QbDVision customer realized, the real answer starts with a question: How can you efficiently transfer knowledge and information when you don’t know where it is, who has it, or what format it’s going to be in?

Solving the tech transfer conundrum

Slow, costly, error-prone tech transfers are often one of the biggest issues drug developers are facing when they come looking for a solution like QbDVision. By the time this customer onboarded our technology, they were already struggling with some of the most common causes of that challenge.

One of the most prominent producers of generic medications, our customer operates multiple manufacturing facilities across the globe and has an established presence in over 20 markets worldwide. But while they had big plans to extend their growth, they had been hampered by several key problems that were all too familiar to our team:

  • Unstructured data: Lack of consistent organization and taxonomies made it difficult to leverage their wealth of existing knowledge.
  • Paper-based systems: Reliance on hard copies left most of the organization with limited access to even their own projects’ information.
  • Limited collaboration: Departmental silos added to the challenge of sharing unstructured information locked in physical formats.

Why were tech transfers so challenging ? The real answer starts with a question: How can you efficiently transfer knowledge and information when you don’t know where it is, who has it, or what format it’s going to be in?

Every one of these limitations was a roadblock in their path to the “right-first-time” development challenges the company wanted to implement. We stepped in to help them remove the cost-driving, time-consuming friction in multiple areas of their business – but especially in their tech transfer processes.

Connecting scattered teams, data & processes with a unified knowledge platform

Data decentralization is an endemic problem in the life sciences, so our customer’s challenges were ones our team had seen many times before. Over the next 18 months, we made it our mission to modernize the structure, exchange, and utilization of data across this busy organization and its workflows.

Over 200 active projects needed to be transferred from a 100% paper-based system to our digital knowledge base – no easy task for us or them. Together, we started the journey with a single pilot project and a few critical goals: 

  1. Craft our customer’s vision for transformation, including clear digitalization objectives.
  2. Identify key stakeholders in their development processes.
  3. Assess their current processes and available data to pinpoint gaps in essential information.
  4. Establish a consistent approach to digitizing their analog workflows.

This initial collaboration gave our team the insights we needed to create a systematic plan for centralizing this knowledge in QbDVision’s unified data framework. The first step: deploying a 4-step Digital CMC process that would put them on the path to measurable improvements in their business performance.

Implementing Digital CMC: The power of Atomize > Structure > Connect > Leverage

At the heart of our customer’s struggles was one of the industry’s hallmark challenges: reliance on documents. Their paper-based systems locked  vital information in static, isolated files, while indexing these documents – instead of the data in the documents – added friction to every workflow that relied on that information.

To help them break out of that trap, we deployed a road-tested process for transforming CMC operations: 

1

Atomize documents by breaking them down to the discrete, individual data objects they contain.

2

Structure those data objects in an information framework with consistent taxonomies.

3

Connect related data objects across the framework to dimensionalize the knowledge and insights they convey.

4

Leverage that framework to enhance decision-making, facilitate collaboration, and automate essential workflows.

Once that process was complete and a unified knowledge base was in place, our customer could immediately see the benefits in multiple key areas of their business:

Accelerated tech transfers

Initially, they struggled with many of the hallmarks of conventional tech transfer processes – including fragmented hand-offs to MS&T and QA, gap analyses hampered by document silos, and tedious risk recalculations at different process scales.

But with their newly centralized knowledge base, they could switch to QbDVision’s Digital Tech Transfer workflow. Our solution enabled them to conduct side-by-side gap analyses, visualize their risks, and streamline knowledge exchange across every site and scale.

The result: Far fewer headaches and months less work.

Supercharged report generation

Like scientists anywhere, experts at this organization weren’t thrilled to be spending the bulk of their time digging raw data out of spreadsheets and manually entering it into sprawling documents. It took them challenging amounts of time to generate reports like the FMEA.

That changed quickly once we centralized our customer’s knowledge and data in QbDVision and fully connected each datapoint to relevant attributes, parameters, and components. In QbDVision’s 21 CFR 11 compliant infrastructure, their scientists could generate reports like the FMEA – fully approved and signed-off – in a matter of hours. Not weeks.

Now that they’ve shrunk their reporting timelines by up to 95%, we don’t see manually wrangling data in their future any time soon.

Visualized risk assessment

With their data consolidated, structured, and contextualized in QbDVision, our customer could visually map potential impact chains throughout their development strategies. This unique feature significantly enhanced their risk assessment and management practices by making it easier to spot the correlation of input and output variables, as well as the impact of changes, variances, and nonconformities.

QbDVision has allowed us to create a standardized framework for development, from R&D to Manufacturing, based on the holistic principles of Quality by Design, FAIR Data, and the ICH Guidelines. Enabling myself and my colleagues in R&D, MS&T, QA, and Project Management to collaborate together within a unified knowledge platform.

Streamlined submissions

In assessing the data management practices within this organization, we quickly found that they had fallen into an all-too-common bad habit: tracking the same data points in multiple different documents in numerous different locations. As a result, supposedly simple updates to unit operations, process parameters, and quality attributes frequently meant tracking down 5-10 different documents across the organization. 

Not surprisingly, this repetitive, time-consuming process often led to data integrity issues and operational inefficiencies, especially when information was captured freestyle in narrative-based documents. They were badly in need of a centralized source of truth where data could be stored, indexed, and exchanged with anyone who needed it – which is exactly what QbDVision provided.

With Doc Builder, templated submissions like the eCTD Module could be easily and directly generated from their centralized, structured knowledge base. Their CMC teams could fly through the pharmaceutical development component of the eCTD*, as well as other key inputs relating to Finished Product Specifications, Control of Critical Steps and Intermediates, Manufacturing Equipment, and the Manufacturing Process. 

*Section P.2 of the eCTD Module 3: Outlines the underlying knowledge that establishes the developed formulation and chosen dosage form that are suitable for their intended use.

SPOTLIGHT

QbDVision's Doc Builder

Create, maintain, review – all in one place

One of users’ favorite QbDVision features, this powerful tool harnesses the power of your data to dynamically create reports in a fully compliant, validated environment. 

  • Automate generation of templated reports like FMEA and eCTD Module 3
  • Customize outputs to your organization’s style and taxonomies
  • Eliminate tedious data consolidation and entry steps

What everyone wants to see: Tangible, measurable business outcomes

For almost 2 years now, QbDVision has been critical to the broader digital transformation strategy – and has delivered some impressive results.

↓95% reporting time

QbDVision’s automated reporting capabilities eliminated duplicate work on FMEA and other development reports. One key reporting task was reduced from 3 weeks to just 6 hours.

Simplified scale-up, process optimization & post-approval change management

Instead of updating several documents in various locations, their CMC teams can eliminate repetitive work and reduce cycle times by updating centralized data for on-market products.

Data-driven audits streamlined by a single source of truth

Auditors can simply log in to QbDVision to get a fully contextualized understanding of both product and process requirements.

3X faster tech transfers

The Digital Tech Transfer workflow accelerated handoffs from R&D to manufacturing, while integrated Transfer Risk eliminated time-consuming risk recalculations at different scales.

Risk management & assessment enhanced by risk-based traceability

Embedded links between CQAs, CPPs, and CMAs facilitate agile risk management practices and reduced cycle times.

Accelerated development of eCTD Module 3 submission

A centralized, validated knowledge hub reinforces data integrity and keeps knowledge from being lost in freestyle, narrative-based documents. 

↓95% reporting time

QbDVision’s automated reporting capabilities eliminated duplicate work on FMEA and other development reports. One key reporting task was reduced from 3 weeks to just 6 hours.

3X faster tech transfers

The Digital Tech Transfer workflow accelerated handoffs from R&D to manufacturing, while integrated Transfer Risk eliminated time-consuming risk recalculations at different scales.

Simplified scale-up, process optimization & post-approval change management

Instead of updating several documents in various locations, their CMC teams can eliminate repetitive work and reduce cycle times by updating centralized data for on-market products.

Data-driven audits streamlined by a single source of truth

Auditors can simply log in to QbDVision to get a fully contextualized understanding of both product and process requirements.

Risk management & assessment enhanced by risk-based traceability

Embedded links between CQAs, CPPs, and CMAs facilitate agile risk management practices and reduced cycle times.

Accelerated development of eCTD Module 3 submission

A centralized, validated knowledge hub reinforces data integrity and keeps knowledge from being lost in freestyle, narrative-based documents. 

↓95% reporting time

QbDVision’s automated reporting capabilities eliminated duplicate work on FMEA and other development reports. One key reporting task was reduced from 3 weeks to just 6 hours.

3X faster tech transfers

The Digital Tech Transfer workflow accelerated handoffs from R&D to manufacturing, while integrated Transfer Risk eliminated time-consuming risk recalculations at different scales.

Simplified scale-up, process optimization & post-approval change management

Instead of updating several documents in various locations, their CMC teams can eliminate repetitive work and reduce cycle times by updating centralized data for on-market products.

Data-driven audits streamlined by a single source of truth

Auditors can simply log in to QbDVision to get a fully contextualized understanding of both product and process requirements.

Risk management & assessment enhanced by risk-based traceability

Embedded links between CQAs, CPPs, and CMAs facilitate agile risk management practices and reduced cycle times.

Accelerated development of eCTD Module 3 submission

A centralized, validated knowledge hub reinforces data integrity and keeps knowledge from being lost in freestyle, narrative-based documents. 

Looking ahead, this customer was planning to extend their paper purge by implementing an eQMS – a complementary system that can fully eliminate their paper-based document management, training management, and supplier management workflows. 

Today, as their digitalization gathers momentum, they’re continuing to migrate their remaining projects to QbDVision. We’re excited and proud to see their ongoing commitment to our platform, Digital CMC, and ultimately, to accelerating the delivery of high-quality, life-changing therapies to patients.

GET IN TOUCH

Want to see results like these on your CMC projects?

Reach out to our team of experts to learn more about what made this collaboration a success – and how we can help put your drug development team on the path to Digital CMC.

Victor Goetz, Ph.D

Executive Director, TS/MS New Modalities and Data Strategy, Eli Lilly and Company

Victor Goetz, Ph.D. is the Executive Director of Technical Services New Modalities and Data Strategy at Eli Lilly and Company. He has over 35 years of industry experience in developing and commercializing nine novel medicines to enhance the exchange of knowledge needed to speed the delivery of new medicines to patients. Dr. Goetz holds a BS in chemical engineering from Stanford University and a PhD in chemical and biochemical engineering from the University of Pennsylvania.

Rachelle Howard

Director of Manufacturing Systems Automation and Digital Strategy, Vertex Pharmaceuticals

Rachelle is the Director of Manufacturing Systems Automation and Digital Strategy for Vertex’s Small Molecule Manufacturing Center. She oversees the site Automation Engineering function and has co-led Vertex’s global Digital Manufacturing Transformation program since 2019. She leads several initiatives related to data integrity, data management, and employee education. Rachelle is a graduate of Tufts University and the University of Connecticut where she has degrees in Chemical Engineering and a PhD in Process Control.

Vijay Raju

Vice President, CMC Management, Flagship Pioneering

Vijay currently leads CMC activities to deliver on Pioneering Medicines portfolio. The portfolio is built on Flagship Pioneering’s bio-platforms covering multiple modalities (small molecules, biologics, cell & gene therapies). Vijay was previously in technical leadership roles at Novartis.

Greg Troiano

Head of cGMP Strategic Supply & Operations, mRNA Center of Excellence, Sanofi

Greg serves as Head of cGMP Strategic Supply and Operations at the mRNA Center of Excellence at Sanofi, where he is responsible for all aspects of clinical production and raw material supply chain. He joined Sanofi via acquisition of Translate Bio, where he was Chief Manufacturing Officer and responsible for Technical Operations. Over his 20+ year career in the drug delivery field, Greg had various roles leading the pharmaceutical development of complex formulations, including numerous nano- and microparticle based systems. Greg received his MSE and BS in Biomedical Engineering from The Johns Hopkins University and was elected and inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2020 for recognition of his accomplishments in drug delivery.

Pat Sacco

Senior Vice President Manufacturing, Quality, and Operations, SalioGen

Pat is a Biotechnology technical operations executive with 30+ years of experience leading and managing technical operations functions at numerous innovative companies in the biotech and life sciences industries. He has a passion for advancing and implementing best practices in pharmaceutical manufacturing.

Diana Bowley

Associate Director, Data & Digital Strategy, AbbVie

Diana is the Associate Director, Data & Digital Strategy in S&T-Biologics Development and Launch leading the organization’s Digital Transformation since October 2021. She joined AbbVie in 2012 in the R&D-Discovery Biologics group focused on antibody and multi-specific protein screening and engineering, leading multiple programs to the cell line development stage. In 2017 she joined Information Research and led a team of IT professionals who supported AbbVie’s Discovery Scientists in Biotherapeutics, Chemistry, Immunology and Neuroscience. She has a PhD in Molecular Biology from The Scripps Research Institute and Bachelor of Science in Chemistry from The University of Northern Iowa.

Robert Dimitri, M.S., M.B.A.

Director Digital Quality Systems, Thermo Fisher Scientific

Robert Dimitri is a Director of Digital Quality Systems in Thermofisher’s Pharma Services Group. Previously he was a Digital Transformation and Innovation Lead in Takeda’s Business Excellence for the Biologics Operating Unit while leading Digital and Data Sciences groups in Manufacturing Sciences at Takeda’s Massachusetts Biologics Site.

Devendra Deshmukh

Global Head, Digital Science Business Operations, Thermo Fisher Scientific

Devendra Deshmukh currently leads Global Business Operations for Digital Science Solutions at Thermo Fisher Scientific. In this role he oversees operations broadly for the business across its product portfolio and leads the global professional services, technical support, and product education teams.

Grant Henderson

Sr. Dir. Manufacturing Science and Technology, VernalBio

Grant Henderson is the Senior Director of Manufacturing Science and Technology at Vernal Biosciences. He has years of expertise in pharmaceutical manufacturing process development/characterization, advanced design of experiments, and principles of operational excellence.

Ryan Nielsen

Life Sciences Global Sales Director, Rockwell Automation

Ryan Nielsen is the Life Sciences Global Sales Director at Rockwell Automation. He has over 17 years of industry experience and a passion for collaboration in solving complex problems and adding value to the life sciences space.

Shameek Ray

Head of Quality Manufacturing Informatics, Zifo

Shameek Ray is the Head of Quality Manufacturing Informatics and Zifo and has extensive experience in implementing laboratory informatics and automation for life sciences, forensics, consumer goods, chemicals, food and beverage, and crop science industries. With his background in services, consulting, and product management, he has helped numerous labs embark on their digital transformation journey.

Max Peterson​

Lab Data Automation Practice Manager, Zifo

Max Petersen is the Lab Data Automation Practice Manager at Zifo responsible for developing strategy for their Lab Data Automation Solution (LDAS) offerings. He has over 20 years of experience in informatics and simulation technologies in life sciences, chemicals, and materials applications.

Michael Stapleton

Board Director, QbDVision

Michael Stapleton is a life sciences leader with success spanning leadership roles in software, consumables, instruments, services, consulting, and pharmaceuticals. He is a constant innovator, optimist, influencer, and digital thought leader identifying the next strategic challenge in life sciences, executing and operationalizing on high impact strategic plans to drive growth.

Matthew Schulze

Head of Digital Pioneering Medicines & Regulatory Systems, Flagship Pioneering

Matt Schulze is a Senior Director in the Flagship Digital, IT, and Informatics team, where he leads and manages the digital evolution for Pioneering Medicines. His role is pivotal in ensuring that digital strategies align with the overall goals and objectives of the Flagship Pioneering initiative.

His robust background in digital life sciences includes expertise in applications, informatics, data management, and IT/OT management. He previously spearheaded Digital Biomanufacturing Applications at Resilience, a CDMO start-up backed by Arch, where he established a team responsible for implementing global manufacturing automation systems, Quality Assurance applications, laboratory systems, and data management applications.

Matt holds a B.S. in Biology and Biotechnology from Worcester Polytechnic Institute and an M.B.A. from the Boston University Questrom School of Business, where he focused on Strategy and Innovation.

Daniel R. Matlis

Founder and President, Axendia

Daniel R. Matlis is the Founder and President of Axendia, an analyst firm providing trusted advice to life science executives on business, technology, and regulatory issues. He has three decades of industry experience spanning all life science and is an active contributor to FDA’s Case for Quality Initiative. Dan is also a member of the FDA’s advisory council on modeling, simulation, and in-silico clinical trials and co-chaired the Product Quality Outcomes Analytics initiative with agency officials.

Kir Henrici

CEO, The Henrici Group

Kir is a life science consultant working domestically and internationally for over 12 years in support of quality and compliance for pharma and biotech. Her deep belief in adopting digital technology and data analytics as the foundation for business excellence and life science innovation has made her a key member of PDA and ISPE – she currently serves on the PDA Regulatory Affairs/Quality Advisory Board

Oliver Hesse

VP & Head of Biotech Data Science & Digitalization, Bayer Pharmaceuticals

Oliver Hesse is the current VP & Head of Biotech Data Science & Digitalization for Bayer, based in Berkeley, California. He has a degree in Biotechnology from TU Berlin and started his career in a Biotech start-up in Germany before joining Bayer in 2008 to work on automation, digitalization, and the application of data science in the biopharmaceutical industry.

John Maguire

Director of Manufacturing Sciences, Sanofi mRNA Center of Excellence

With over 18 years of process engineering experience, John is an expert in the application of process engineering and operational technology in support of the production of life science therapeutics. His work includes plant capability analysis, functional specification development, and the start-up of drug substance manufacturing facilities in Ireland and the United States.

Chris Kopinski

Business Development Executive, Life Sciences and Healthcare at AWS

As a Business Development Executive at Amazon Web Services, Chris leads teams focused on tackling customer problems through digital transformation. This experience includes leading business process intelligence and data science programs within the global technology organizations and improving outcomes through data-driven development practices.

Tim Adkins

Digital Life Science Operations, ZÆTHER

Tim Adkins is a Director of Digital Life Sciences Operations at ZÆTHER, serving the life science industry by assisting companies reach their desired business outcomes through digital IT/OT solutions. He has 30 years of industry experience as an IT/OT leader in global operational improvements and support, manufacturing system design, and implementation programs.

Blake Hotz

Manufacturing Sciences Data Manager, Sanofi

At Sanofi’s mRNA Center of Excellence, Blake Hotz focuses on developing data ingestion and cleaning workflows using digital tools. He has over 5 years of experience in biotech and holds degrees in Chemical Engineering (B.S.) and Biomedical Engineering (M.S.) from Tufts University.

Anthony DeBiase

Offering Manager, Rockwell Automation

Anthony has over 14 years of experience in the life science industry focusing on process development, operational technology (OT) implementation, technology transfer, CMC and cGMP manufacturing in biologics, cell therapies, and regenerative medicine.

Andy Zheng

Data Solution Architect, ZÆTHER

Andy Zheng is a Data Solution Architect at ZÆTHER who strives to grow and develop cutting-edge solutions in industrial automation and life science. His years of experience within the software automation field focused on bringing innovative solutions to customers which improve process efficiency.

Sue Plant

Phorum Director, Regulatory CMC, Biophorum

Sue Plant is the Phorum Director of Regulatory CMC at BioPhorum, a leading network of biopharmaceutical organizations that aims to connect, collaborate, and accelerate innovation. With over 20 years of experience in life sciences, regulatory, and technology, she focuses on improving access to medicines through innovation in the regulatory ecosystem.

Yash Sabharwal​

President & CEO, QbDVision

Yash Sabharwal is an accomplished inventor, entrepreneur, and executive specializing in the funding and growth of early-stage technology companies focused on life science applications. He has started 3 companies and successfully exited his last two, bringing a wealth of strategic and tactical experience to the team.

Joschka Buyel

Senior MSAT Scientist at Viralgen, Process and Knowledge Management Scientist at Bayer AG

Joschka is responsible for the rollout and integration of QbDVision at Bayer Pharmaceuticals. He previously worked on various late-stage projects as a Quality-by-Design Expert for Product & Process Characterization, Process Validation, and Transfers. Joschka has a Ph.D. in Drug Sciences from Bonn University and a M.S. and B.S. in Molecular and Applied Biotechnology from the RWTH University.

Luke Guerrero

COO, QbDVision

A veteran technologist and company leader with a global CV, Luke currently oversees the core business operations across QbDVision and its teams. Before joining QbDVision, he developed, grew, and led key practices for international agency Brand Networks, and spent six years deploying technology and business strategies for PricewaterhouseCoopers’ CIO Advisory consulting unit.

Gloria Gadea Lopez

Head of Global Consultancy, Business Platforms | Ph.D., Biosystems Engineering

Gloria Gadea-Lopez is the Head of Global Consultancy at Business Platforms. Using her prior extensive experience in the biopharmaceutical industry, she supports companies in developing strategies and delivering digital systems for successful operations. She holds degrees in Chemical Engineering, Food Science (M.S.), and Biosystems Engineering (Ph.D.)

Speaker Name

Speaker’s Pretty Long Title, Specialty, and Business

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam dignissim velit et est ultricies, a commodo mauris interdum. Etiam sed ante mi. Aliquam vestibulum faucibus nisi vel lacinia. Nam suscipit felis sed erat varius mollis. Mauris diam diam, viverra nec dolor et, sodales volutpat nulla. Nam in euismod orci.